121 related articles for article (PubMed ID: 36811544)
1. IMPACT OF TUMOR MOLECULAR PHENOTYPE ON SURVIVAL OF PATIENTS WITH GASTRIC CANCER AFTER RADICAL SURGERY.
Dumanskyi YV; Kirkilevskyi SI; Sulaeva OM; Polyasnyi VO; Mashukov AO; Kovalevska LA; Yarema RR; Ogorchak MA
Exp Oncol; 2022 Dec; 44(4):324-326. PubMed ID: 36811544
[TBL] [Abstract][Full Text] [Related]
2. Correlation of human epidermal growth factor receptor 2 expression with clinicopathological characteristics and prognosis in gastric cancer.
He C; Bian XY; Ni XZ; Shen DP; Shen YY; Liu H; Shen ZY; Liu Q
World J Gastroenterol; 2013; 19(14):2171-8. PubMed ID: 23599643
[TBL] [Abstract][Full Text] [Related]
3. Immunoexpression of PTEN, HER2/neu, and Ki-67 in endoscopic gastric carcinoma biopsies; their correlation with histological subtypes and one-year survival.
Acharya S; Thakur B; Mittal R
Indian J Pathol Microbiol; 2022; 65(1):29-34. PubMed ID: 35074962
[TBL] [Abstract][Full Text] [Related]
4. Comparative study on overexpression of HER2/neu and HER3 in gastric cancer.
Zhang XL; Yang YS; Xu DP; Qu JH; Guo MZ; Gong Y; Huang J
World J Surg; 2009 Oct; 33(10):2112-8. PubMed ID: 19636613
[TBL] [Abstract][Full Text] [Related]
5. An independent survival prognostic role for human epidermal growth factor receptor 2 in gastric cancer: evidence from a meta-analysis.
Wang Y; He L; Cheng Y
Clin Transl Oncol; 2018 Feb; 20(2):212-220. PubMed ID: 28681313
[TBL] [Abstract][Full Text] [Related]
6. Development and Validation of an Easy-to-Implement, Practical Algorithm for the Identification of Molecular Subtypes of Gastric Cancer: Prognostic and Therapeutic Implications.
Koh J; Lee KW; Nam SK; Seo AN; Kim JW; Kim JW; Park DJ; Kim HH; Kim WH; Lee HS
Oncologist; 2019 Dec; 24(12):e1321-e1330. PubMed ID: 31371521
[TBL] [Abstract][Full Text] [Related]
7. Relationship of p53 and c-erbB-2 expression to histopathological features, Helicobacter pylori infection and prognosis in gastric cancer.
Shun CT; Wu MS; Lin JT; Chen SY; Wang HP; Lee WJ; Wang TH; Chuang SM
Hepatogastroenterology; 1997; 44(14):604-9. PubMed ID: 9164544
[TBL] [Abstract][Full Text] [Related]
8. HER2 expression and its clinicopathological features in resectable gastric cancer.
Kataoka Y; Okabe H; Yoshizawa A; Minamiguchi S; Yoshimura K; Haga H; Sakai Y
Gastric Cancer; 2013 Jan; 16(1):84-93. PubMed ID: 22410801
[TBL] [Abstract][Full Text] [Related]
9. Incorporation of p-53 mutation status and Ki-67 proliferating index in classifying Her2-neu positive gastric adenocarcinoma.
Ahmed A; Al-Tamimi DM
Libyan J Med; 2018 Dec; 13(1):1466573. PubMed ID: 29697008
[TBL] [Abstract][Full Text] [Related]
10. HER2 amplification detected in the circulating DNA of patients with gastric cancer: a retrospective pilot study.
Shoda K; Masuda K; Ichikawa D; Arita T; Miyakami Y; Watanabe M; Konishi H; Imoto I; Otsuji E
Gastric Cancer; 2015 Oct; 18(4):698-710. PubMed ID: 25322965
[TBL] [Abstract][Full Text] [Related]
11. Integration of transcriptomics, proteomics, and metabolomics data to reveal HER2-associated metabolic heterogeneity in gastric cancer with response to immunotherapy and neoadjuvant chemotherapy.
Yuan Q; Deng D; Pan C; Ren J; Wei T; Wu Z; Zhang B; Li S; Yin P; Shang D
Front Immunol; 2022; 13():951137. PubMed ID: 35990657
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of HER2/neu expression in gastric cancer.
Ananiev J; Gulubova M; Manolova I; Tchernev G
Wien Klin Wochenschr; 2011 Jul; 123(13-14):450-4. PubMed ID: 21739203
[TBL] [Abstract][Full Text] [Related]
13. Prognosis of HER2 over-expressing gastric cancer patients with liver metastasis.
Dang HZ; Yu Y; Jiao SC
World J Gastroenterol; 2012 May; 18(19):2402-7. PubMed ID: 22654433
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of mutant p53 and c-erbB-2 proteins and mutations of the p15 and p16 genes in human gastric carcinoma: with respect to histological subtypes and stages.
Wu MS; Shun CT; Sheu JC; Wang HP; Wang JT; Lee WJ; Chen CJ; Wang TH; Lin JT
J Gastroenterol Hepatol; 1998 Mar; 13(3):305-10. PubMed ID: 9570245
[TBL] [Abstract][Full Text] [Related]
15. Different effects of p53 protein overexpression on the survival of gastric cancer patients according to Lauren histologic classification: a retrospective study.
Kim KW; Kim N; Choi Y; Kim WS; Yoon H; Shin CM; Park YS; Lee DH; Park YS; Ahn SH; Park DJ; Kim HH; Lee HS; Kim JW; Kim JW; Lee KW; Chang W; Park JH; Lee YJ; Lee KH; Kim YH
Gastric Cancer; 2021 Jul; 24(4):844-857. PubMed ID: 33598811
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes.
Kim MJ; Ro JY; Ahn SH; Kim HH; Kim SB; Gong G
Hum Pathol; 2006 Sep; 37(9):1217-26. PubMed ID: 16938528
[TBL] [Abstract][Full Text] [Related]
17. Molecular breast cancer subtypes in premenopausal and postmenopausal African-American women: age-specific prevalence and survival.
Ihemelandu CU; Leffall LD; Dewitty RL; Naab TJ; Mezghebe HM; Makambi KH; Adams-Campbell L; Frederick WA
J Surg Res; 2007 Nov; 143(1):109-18. PubMed ID: 17950079
[TBL] [Abstract][Full Text] [Related]
18. Impact of c-erbB-2 protein on 5-year survival rate of gastric cancer patients after surgery: a cohort study and meta-analysis.
Wu H; Cai Z; Lu G; Cao S; Huang H; Jiang Y; Sun W
Tumori; 2017 May; 103(3):249-254. PubMed ID: 26549693
[TBL] [Abstract][Full Text] [Related]
19. Impact of expression of human epidermal growth factor receptors EGFR and ERBB2 on survival in stage II/III gastric cancer.
Terashima M; Kitada K; Ochiai A; Ichikawa W; Kurahashi I; Sakuramoto S; Katai H; Sano T; Imamura H; Sasako M;
Clin Cancer Res; 2012 Nov; 18(21):5992-6000. PubMed ID: 22977193
[TBL] [Abstract][Full Text] [Related]
20. HER2 expression in gastric cancer: Rare, heterogeneous and of no prognostic value - conclusions from 924 cases of two independent series.
Grabsch H; Sivakumar S; Gray S; Gabbert HE; Müller W
Cell Oncol; 2010; 32(1-2):57-65. PubMed ID: 20208134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
